(MNPR) – Globe Newswire
-
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
-
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
-
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
-
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
-
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
-
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
-
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
-
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
-
Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments
-
Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
-
Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference
-
Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
-
Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments
-
Monopar Provides Encouraging Camsirubicin Clinical Data Update
-
Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore
-
Monopar to Participate in the Radiopharma Forum by the Lake 2023
-
Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference
-
Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update
-
Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments
-
Monopar to Present at the Jefferies Radiopharma Innovation Summit
-
Monopar to Present at the Jefferies Radiopharma Innovation Summit
-
Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis
-
Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis
-
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments
-
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments
-
Monopar to Present at the 35th Annual Roth Conference
-
Monopar to Present at the 35th Annual Roth Conference
-
Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials
-
Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials
-
Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin
-
Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin
-
Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT
-
Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT
-
Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2
-
Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2
-
Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration
-
Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration
-
Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial
-
Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial
-
Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments
-
Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments
-
Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202
-
Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202
-
Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting
-
Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting
-
Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting
-
Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting
-
Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis
-
Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis
-
Monopar to Present at Roth Inaugural Healthcare Opportunities Conference
Back to MNPR Stock Lookup
